Scalper1 News
The year’s biggest cancer meeting brought a raft of updates in the hot oncology market, sending stocks moving as Wall Street sorted out the winners and losers. The biggest upside surprise from the American Society for Clinical Oncology meeting in Chicago, which ends Tuesday, probably came from ImmunoGen (IMGN), a beleaguered biotech that came back to life thanks to its antibody drug conjugate (ADC) mirvetuximab soravtansine, or IMGN853. The drug’s Scalper1 News
Scalper1 News